Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Biofrontera Inc is a biopharmaceutical company specializing in the commercialization of pharmaceutical products for the treatment of dermatological conditions, diseases caused by exposure to sunlight that result in sun damage to the skin. Its licensed products focus on the treatment of actinic kerat... Biofrontera Inc is a biopharmaceutical company specializing in the commercialization of pharmaceutical products for the treatment of dermatological conditions, diseases caused by exposure to sunlight that result in sun damage to the skin. Its licensed products focus on the treatment of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer. It also markets a topical antibiotic for the treatment of impetigo, a bacterial skin infection. Mehr anzeigen
Last patient completed 1 year follow-up of study ALA-BCC-CT013 in December 2024.Data from follow-up will be included in FDA submission, expected in Q3 2025.Biofrontera announced highly...
Biofrontera started commercial distribution of the RhodoLED XL in June 2024 and has seen rapid uptake in the US market since launch.The RhodoLED XL is approved by the FDA in combination with...
WOBURN, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and...
●Total revenues for the third quarter 2024 were $9.0 million, an increase of 1.5% from Q3 2023. Revenue increase would have been 19% if shipments were not delayed due to Hurricane...
First Phase 3 PDT study in patients with sBCC in the United States.Primary and secondary endpoints all highly statistically significant p<0.0001Correlates to data seen in Europe where sBCC is...
First Phase 3 PDT study in patients with sBCC in the United States.Rigorous dual endpoints requiring complete clinical and cytological clearance of malignant lesions.Data now being analyzed...
Approval allows for larger field treatment of actinic keratosis (AK) on face and scalp with Ameluz®-PDT using the BF-RhodoLED or the RhodoLED XL lampSupplemental New Drug Application (sNDA...
Woburn, MA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.01 | -0.892857142857 | 1.12 | 1.87 | 0.96 | 3835886 | 1.17301166 | CS |
| 4 | 0.1 | 9.90099009901 | 1.01 | 1.87 | 0.939115 | 1096114 | 1.15313127 | CS |
| 12 | 0.17 | 18.085106383 | 0.94 | 2.22 | 0.651266 | 3531335 | 1.15481615 | CS |
| 26 | 0.02 | 1.83486238532 | 1.09 | 2.22 | 0.651266 | 1772639 | 1.15116606 | CS |
| 52 | -1.21 | -52.1551724138 | 2.32 | 2.4302 | 0.61 | 1108483 | 1.14749218 | CS |
| 156 | -97.09 | -98.8696537678 | 98.2 | 122.4 | 0.61 | 746472 | 33.40180808 | CS |
| 260 | -80.69 | -98.6430317848 | 81.8 | 292.6 | 0.61 | 2023574 | 104.63872922 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
